In particular, circulating levels of both soluble JAM-A (sJAM-A) and soluble JAM-C (sJAM-C) were found to be significantly increased in SSc patients with respect to healthy controls, especially in those featuring early/active NVC patterns and ischemic DUs [36,37]. This evidence concerns the gene F11R and systemic sclerosis.